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NNN
1 is a tobacco-specific nitrosamine formed by nitrosation of the tobacco alkaloids nornicotine and nicotine (Hu et al., 1974; Hecht et al., 1978) . It is the most prevalent strongly carcinogenic nitrosamine in smokeless tobacco products, such as chewing tobacco and snuff, and occurs in substantial quantities in cigarette smoke (Hoffmann et al., 1994) . NNN causes tumors of the esophagus and nasal mucosa in rats, respiratory tract in hamsters, and lung in mice (Hecht, 1998) . When NNN was administered to rats together with NNK, oral cavity tumors resulted (Hecht et al., 1986) . NNN is likely to play an important role as a cause of esophageal cancer in smokers and oral cavity tumors in people who use smokeless tobacco products (Hoffmann and Hecht, 1990) .
Metabolic activation of NNN is a prerequisite for its mutagenicity, DNA binding, and most likely its carcinogenicity Hecht, 1998) . The metabolism of NNN in rodents is summarized in Fig. 1 (Hecht, 1998) . Pyridine-N-oxidation produces NNN-N-oxide, whereas denitrosation and oxidation yield norcotinine. These two pathways result in detoxification of NNN. The major hydroxylation reactions occur ␣Ϫ to the N-nitroso group, yielding 2Ј-hydroxyNNN and 5Ј-hydroxyNNN. 2Ј-HydroxyNNN undergoes spontaneous ring opening, producing a diazohydroxide, which reacts with H 2 O yielding a keto alcohol. This keto alcohol is then metabolically oxidized to a keto acid or reduced to a diol. Alternatively, 2Ј-hydroxyNNN can lose nitrous acid, yielding myosmine. 5Ј-Hydroxylation of NNN gives 5Ј-hydroxyNNN, which ring opens to a diazohydroxide that reacts with H 2 O producing a lactol. This lactol is metabolically converted to a hydroxy acid, either directly or through a lactone. Studies to date indicate that 2Ј-hydroxylation of NNN is its major metabolic activation pathway, yielding target tissue DNA adducts that release the keto alcohol upon hydrolysis (Hecht, 1998) . Minor hydroxylation pathways also occur at the 3Ј-and 4Ј-positions of NNN, yielding the stable metabolites 3Ј-hydroxyNNN and 4Ј-hydroxyNNN.
We are particularly interested in identifying a urinary metabolite of NNN that could be used as a biomarker of its uptake in humans exposed to tobacco products. This represents a considerable challenge because studies in rodents have shown that NNN itself is extensively This study was supported by Grants CA-44377 and CA-81301 from the National Cancer Institute 1 Abbreviations used are: NNN, NЈ-nitrosonornicotine; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN-N-oxide, NЈ-nitrosonornicotine-1-N-oxide; keto alcohol, 4-hydroxy-1-(3-pyridyl)-1-butanone; keto acid, 4-oxo-4-(3-pyridyl)butyric acid; diol, 4-hydroxy-4-(3-pyridyl)-1-butanol; lactol, 2-hydroxy-5-(3-pyridyl)tetrahydrofuran; hydroxy acid, 4-hydroxy-4-(3-pyridyl)butyric acid; lactone, 5-(3-pyridyl)tetrahydrofuran-2-one; HPLC, high-performance liquid chromatography; MS, mass spectometry; GC, gas chromatography; CI, chemical ionization; MS/MS, tandem mass spectometry; PBS, phosphate-buffered saline; AUC, area under the curve.
metabolized and its known major urinary metabolites such as the hydroxy acid and keto acid are also metabolites of nicotine. Since nicotine levels in tobacco products are as much as 10,000 times greater than those of NNN, the hydroxy acid and keto acid cannot be used as specific biomarkers of NNN uptake Trushin and Hecht, 1999) . Metabolites of NNN that retain unique structural features related to NNN, such as NNN-N-oxide, 3Ј-hydroxyNNN, and 4Ј-hydroxyNNN, are relatively minor urinary metabolites in rodents. It is possible that the qualitative or quantitative aspects of NNN metabolism could differ in rodents and primates. We have observed such differences in the metabolism of the related nitrosamine NNK . The results of those studies ultimately led to the development of an assay for uptake of NNK in humans by measurement of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronide in urine Hecht, 1998) . Therefore, in this study, we examined the metabolism of NNN in the patas monkey. There has been only one previous investigation of NNN metabolism in a nonhuman primate (Castonguay et al., 1985) . The tissue distribution of NNN and its metabolites was explored in the marmoset monkey (Callithrix jacchus) by whole body autoradiography and HPLC analysis of tissues. The metabolites illustrated in Fig. 1 were detected in several tissues and in urine, but limited structural and quantitative data were available.
Materials and Methods

Instrumentation.
1 H NMR data were obtained on either a 600 or 800 MHz instrument (Varian Medical Systems, Inc., Palo Alto, CA). MS were run on Finnigan TSQ 7000 and LCQ-Deca instruments (Thermo Finnigan MAT/ Thermoquest, San Jose, CA), and a Finnigan MAT 90/95 instrument (Thermo Finnigan MAT GmbH, Bremen, Germany). GC-MS was carried out with a model 6890 gas chromatograph equipped with an autosampler and model 5973 mass selective detector (Agilent Technologies, Wilmington, DE) . HPLC was performed with a Waters Associates system equipped with a model 440 UV detector and a ␤-RAM radioflow detector (IN/US Systems, Tampa, FL).
Chemicals. Racemic [5-3 H]NNN (1.9 Ci/mmol, tritium at the 5-position of the pyridine ring) was purchased from ChemSyn Laboratories (Lenexa, KS). NNN and its metabolites were synthesized (McKennis et al., 1964; Hu et al., 1974; Chen et al., 1978; Hecht et al., 1980; Upadhyaya et al., 2001) . trans-3Ј-Hydroxycotinine and norcotinine were purchased from Toronto Research Chemicals (Toronto, ON, Canada). cis-3Ј-Hydroxycotinine was a gift from Dr. Shantu Amin, American Health Foundation (Valhalla, NY). Norcotinine-1N-oxide and 3Ј-methoxycotinine were prepared as described below. All other chemicals were purchased from Aldrich Chemical Co., (Milwaukee, WI).
Norcotinine-1N-Oxide. Norcotinine (0.005 mmol) was dissolved in CH 2 Cl 2 (5 ml), and m-chloroperbenzoic acid (0.09 mmol) was added. The reaction mixture was stirred overnight at room temperature. The solvent was removed at reduced pressure, and the residue was purified using HPLC system 1 (retention time 16 min) and 2 (retention time 20 min) to yield norcotinine-1N-oxide. 3-Methoxycotinine. Trans-or cis-3Ј-hydroxycotinine (0.01 mmol) was dissolved in 0.5 ml of DMSO. NaH (0.02 mmol) was added, and the reaction mixture was stirred for 5 min. CH 3 I (0.02 mmol) was added, and the reaction dmd.aspetjournals.org mixture was stirred for 10 min. The reaction was quenched by addition of 0.5 ml H 2 O. The mixture was purified by HPLC using a 4.6 ϫ 200 mm Luna C 18 column (Phenomenex, Torrence, CA) with elution by 100% 10 mM ammonium acetate, pH 6.5, to 100% methanol in 40 min at a flow rate of 1 ml per min, retention time 22 min. This gave 0.003 mmol (30%) trans-or cis-3Ј- 3Ј-Hydroxynorcotinine, collected from monkey urine using HPLC system 2, was similarly derivatized.
Animal Experiments. Male patas monkeys were housed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals at Bioqual, Inc. (Rockville, MD). Four experiments were carried out.
In experiment 1, monkey R-234 (4.8 kg) was injected i.v. with ϳ302 Ci (4 g/kg) [5-
3 H]NNN in 1.8-ml sterile phosphate-buffered saline (PBS). In experiment 2, monkey R-238 (4.1 kg) was injected i.v. with ϳ336 Ci (7.6 g/kg) in 1.8 ml PBS. In experiment 3, monkey R-241 (3.0 kg) was injected i.v. with ϳ381 Ci (11.8 g/kg) in 1.8 ml PBS. For collection of metabolites, experiment 4 was carried out. Monkey R-238 (4.1 kg) was injected i.v. with ϳ422 Ci (12.7 mg/kg) in 1.8 ml PBS.
Urine samples were collected at intervals of 0 to 2, 2 to 6, 6 to 24 h. Blood samples were collected at 2, 5, 10, 30, 60, 90, 120, 240, and 360 min after injection, then centrifuged at 2000 rpm for 30 min. Serum and urine samples Peaks number 1-6 are 1, hydroxy acid; 2, 3Ј-hydroxynorcotinine-O-glucuronide; 3, norcotinine-1N-oxide; 4, keto acid; 5, 3Ј-hydroxynorcotinine; 6, norcotinine; and 7, NNN. Structures of the metabolites are shown in Fig. 6 .
FIG. 3. Scheme for identification of 3Ј-hydroxynorcotinine by conversion to 3Ј-methoxycotinine and 3Ј-acetoxy-NЈ-acetylnorcotinine.
The urinary metabolite was methylated or acetylated to give the structures illustrated. The methylated material was identified as a mixture of cis-and trans-3Ј-methoxycotinine by comparison to standards prepared by methylation of cis-or trans-3Ј-hydroxycotinine. Inset, HPLC analysis of standard 3Ј-methoxycotinine and methylated 3Ј-hydroxynorcotinine from monkey urine.
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Analytical Methods. Serum was purified by ultrafiltration using an Amicon Centrifree micropartition system (Millipore Corporation, Bedford, MA) prior to HPLC analysis. Urine samples were centrifuged at 6000 rpm and filtered through a 0.45 m ϫ 3 mm Acrodisc (Gelman Sciences, Ann Arbor, MI) prior to HPLC analysis. Some samples were subjected to enzyme hydrolysis as follows. A 0.5-ml aliquot of urine was adjusted to pH 7.0 and treated with 20,000 units of ␤-glucuronidase (type-1XA from Escherichia coli; SigmaAldrich, St. Louis, MO). The mixture was incubated at 37°C for 12 h and filtered through a Centrifree-YM 30 filter (Millipore Corporation) prior to HPLC analysis. Metabolites and synthetic standards were analyzed by reverse phase HPLC using system 1, a 300 ϫ 3.9 mm, Phenomenex C 18 Bondclone 10-column (Phenomenex), with elution by a linear gradient from 10 mM ammonium acetate, pH 6.5, to 30% methanol at 1 ml/min in 60 min or system 2, isocratic elution with 10 mM ammonium acetate containing 1% methanol. For collection of urinary metabolites, a semipreparative 300 ϫ 7.80 mm Phenomenex C 18 Bondclone 10-column was used, and the HPLC conditions were the same as system 1 except the flow rate was 3 ml/min.
For GC-MS analysis, fractions corresponding to labeled urinary metabolites were evaporated to dryness, redissolved in acetonitrile, and analyzed using a 30 m ϫ 0.32 mm i.d., 0.25-m film thickness, DB-1701 column (J & W Scientific, Folsom, CA). The injection port temperature was 250°C, and the injection mode was splitless. The oven temperature was 90°C for 5.0 min, then raised at 10°C per min to 240°C, and held for 15 min. The carrier gas was He at a flow rate of 1.3 ml/min.
Acetylation of 3-Hydroxynorcotinine. Urinary 3Ј-hydroxynorcotinine (5 Ci) was collected by HPLC. It was dissolved in 1-ml ethyl acetate and to this was added 4-dimethylaminopyridine (4 mg) followed by acetic anhydride (0.1 ml). The reaction mixture was stirred overnight at room temperature then quenched by addition of 1 ml H 2 O. The product was collected by HPLC system 1, retention time 59 min. Pharmacokinetic Data Analysis. The serum concentration versus time data for NNN and its metabolites in experiments 1 to 3 were analyzed by noncompartmental analysis (Gibaldi and Perrier, 1982) . The slope of the terminal phase of the serum concentration rate versus time curve was determined by fitting the data to a monoexponential equation. The terminal rate constant, , was determined from the slope. For both NNN and its metabolites, the area under the serum concentration-time curves from time 0 to time t [AUC (0-t)] was determined by the linear trapezoidal rule up to the last measured concentration. The AUC (t-ϱ) was determined by dividing the last measured concentration by the terminal rate constant . The AUC (0-ϱ) was the sum of the two partial AUCs. The elimination half-life (t 1/2 ) was calculated as 0.693 divided by . The total body clearance (CL) for NNN was calculated as
where D is the intravenous dose of NNN. The steady-state volume of distribution of NNN was calculated as
where AUMC was the area under the first moment of the plasma concentration-time curve.
The renal clearance (CL R ) of NNN and metabolites were calculated as
FIG. 4. GC-positive ion CI-MS analysis of material obtained upon methylation of urinary 3Ј-hydroxynorcotinine.
A, separation of cis-and trans-3Ј-methoxycotinine formed upon methylation of urinary 3Ј-hydroxynorcotinine; B, MS of trans-3Ј-methoxycotinine formed in this reaction; and C, MS of cis-3Ј-methoxycotinine formed in this reaction. Identical spectra were obtained from standards. where Xu was the amount of drug collected in the urine up to 24 h. However, renal clearance could only be determined for those metabolites for which there were both serum and urine data. The time at which the maximal concentration occurred (t max ) was determined by direct observation of the concentration-time data. Fig. 2 . Peak 1 was identified as the hydroxy acid by coelution with a standard. The assignment was confirmed by converting the urinary hydroxy acid to its methyl ester then allowing it to react with (S)-(Ϫ)␣-methylbenzyl isocyanate, as described previously (Trushin and Hecht, 1999) . The resulting carbamate diastereomers coeluted with standards. Peak 4 was identified as the keto acid by coelution with a standard and by reduction to the hydroxy acid upon treatment with NaBH 4 .
Results
Identification of Metabolites. Urine samples were analyzed by HPLC with radioflow detection. A typical chromatogram of 24-h urinary metabolites is illustrated in
Peaks 2, 3, and 5 did not correspond in retention time to any known metabolites of NNN. Treatment of the urine with ␤-glucuronidase caused Peak 2 to disappear with a corresponding increase in Peak 5. The same result was obtained when collected Peak 2 was treated with ␤-glucuronidase. Peak 2 was stable to basic conditions-1N NaOH, 80°C, 1h -that cleave pyridine-N-glucuronides. These results indicated that Peak 2 was an O-glucuronide and that Peak 5 was its aglycone. Electrospray ionization-MS analysis of collected Peak 5 gave a molecular ion of m/z 178, with prominent fragments at m/z 135 (85%) and m/z 106 (100%). CI-MS analysis (NH 3 ) gave a base peak of m/z 179. Acetylation of Peak 5 followed by atmospheric pressure chemical ionization-MS analysis produced a base peak of m/z 263, corresponding to addition of 2 acetyl groups. MS/MS analysis of m/z 263 gave daughter ions at m/z 221 and 179. These results are also consistent with the presence of two acetyl groups. Therefore, there were two protons in the metabolite that could be replaced by acetyl groups. The results suggested that the unknown aglycone, Peak 5, was 3Ј-hydroxynorcotinine (Fig. 3) . This compound has not been reported in the literature, and we were unable to synthesize it. Therefore, we confirmed its identity as illustrated in Fig. 3 . Peak 5 was methylated with NaH and CH 3 I. This produced a new HPLC peak with retention time identical to that of both cis-and trans-3Ј-methoxycotinine (inset of Fig. 3 ), which were prepared by methylation of the known compounds, cis-and trans-3Ј-hydroxycotinine. Further evidence was obtained by GC-MS analysis of the methylated metabolite (Fig. 4) . The two peaks coeluted with standard cis-and trans-3Ј-methoxycotinine and had MS essentially identical to those of standards. These results demonstrate that Peak 5 is a mixture of cis-and trans-3Ј-hydroxynorcotinine, with a cis-/trans-ratio of approximately 40:60. Peak 2 is therefore 3Ј-hydroxynorcotinine-O-glucuronide.
FIG. 5. A, Chromatogram obtained upon HPLC analysis (system 2) of standard norcotinine-1N-oxide and metabolite peak 3 from patas monkey urine; and B, CI-MS
(NH 3 ) of standard and urinary metabolite.
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at ASPET Journals on September 21, 2017 dmd.aspetjournals.org CI-MS analysis of Peak 3 gave a base peak of m/z 179, which could be M ϩ 1 of norcotinine-1N-oxide. This compound was synthesized by treatment of norcotinine with m-chloroperbenzoic acid. The HPLC retention times of the metabolite and standard were identical in HPLC systems 1 and 2 (Fig. 5A) . The CI-MS of synthetic norcotinine-1N-oxide and the metabolite were essentially identical (Fig. 5B) . GC-MS analysis of norcotinine-1N-oxide and the metabolite further confirmed the identity of this metabolite.
Peaks 6 and 7 were identified as norcotinine and NNN by comparison of their HPLC retention times to those of standards. GC-MS analysis of peak 6 collected from HPLC confirmed the assignment as norcotinine.
We also considered the possible formation of pyridyl-N-␤-Dglucopyranuronosyl-NЈ-nitrosonornicotinium inner salt, which eluted at 7 min in HPLC system 1. There was no indication of the presence of this metabolite in urine. Moreover, treatment of the urine with ␤-glucuronidase did not result in an increase in the NNN peak.
Relative amounts of the metabolites in 24 h urine were (% of radioactivity eluting from HPLC Ϯ S.D.) hydroxy acid (43.8 Ϯ 4.0), 3Ј-hydroxynorcotinine-O-glucuronide (5.4 Ϯ 1.0), norcotinine-1N-oxide (16.5 Ϯ 1.3), keto acid (2.7 Ϯ 0.66), 3Ј-hydroxynorcotinine (16.9 Ϯ 2.0), norcotinine (13.1 Ϯ 2.7), and NNN (0.63 Ϯ 0.15), respectively. Metabolite structures are illustrated in Fig. 6 . 
FIG. 7. Mean serum concentration-time profile (n ϭ 3) for NNN and its metabolites in the patas monkey.
Symbols are NNN (F), hydroxy acid (E), norcotinine (ࡗ), 3Ј-hydroxynorcotinine (X), norcotinine-1N-oxide (Ⅺ).
Analysis of pharmacokinetic parameters (Fig. 7, Tables 1 and 2 ) demonstrated that NNN was rapidly eliminated from the body in an apparent monoexponential manner with an elimination half-life of 26.8 Ϯ 12.7 min. Its mean total body clearance was 86.2 Ϯ 24.5 ml/min, and its volume of distribution at steady state was 0.58 Ϯ 0.32 L/kg. Less than 1% of NNN was excreted unchanged in the urine, with a renal clearance of 0.27 Ϯ 0.24 ml/min. The two major metabolites in serum were the hydroxy acid and norcotinine, as indicated by the metabolite/NNN AUC ratios.
NNN was rapidly metabolized to the hydroxy acid, with its maximal serum concentration (t max ) occurring at 30 min. The hydroxy acid had an apparent elimination half-life of 42.1 Ϯ 16.3 min, which was not significantly different from that of NNN, indicating a formation rate-limitation on the elimination of hydroxy acid ( Table 2 ). The formation of norcotinine was somewhat delayed with a t max of 80 Ϯ 35 min. It was very slowly eliminated, once formed, with an elimination half-life of 198.7 Ϯ 128 min. The slow formation of its sequential metabolite, norcotinine-1-N-oxide, was consistent with the kinetics of norcotinine. The t max for the norcotinine-1-N-oxide was 90 Ϯ 30 min and its half-life was 162.4 Ϯ 54.4 min. There was no significant difference in either t max or elimination half-life of norcotinine and norcotinine-1-N-oxide, indicating that the N-oxide elimination was formation-rate limited.
3Ј-Hydroxynorcotinine was formed relatively quickly after the dose of NNN with a t max of 40 Ϯ 17 min but was in significantly lower concentrations than the two primary serum metabolites, the hydroxy acid and norcotinine. Its half-life was 174 Ϯ 26.8 min, which was significantly longer than that of NNN, but not significantly different from that of norcotinine. The half-life data are consistent with 3Ј-hydroxynorcotinine being either formed directly from NNN or formed from norcotinine. The t max of 3Ј-hydroxynorcotinine appears to be shorter than that of norcotinine, a finding that would not support its formation from norcotinine. However, the difference in the t max values did not reach statistical significance.
Discussion
The results of this study demonstrate considerable differences between NNN metabolism in rodents and patas monkeys. In rodents, the major urinary metabolites of NNN are the keto acid and hydroxy acid, resulting from 2Ј-hydroxylation and 5Ј-hydroxylation, as illustrated in Fig. 1 . Relatively small amounts of norcotinine and NNN-N-oxide are observed, whereas the other metabolites of Fig. 1 are barely detectable in rodent urine (Hecht, 1998) . A common feature of rodent and monkey metabolism of NNN is the relatively large amount of the hydroxy acid in urine. However, norcotinine-1N-oxide and 3Ј-hydroxynorcotinine are found in patas monkey urine but not in rodent urine. In addition, the amount of norcotinine in patas monkey urine is considerably greater than that observed in rodent urine. Finally, there is less of the keto acid in patas monkey urine than in rodent urine.
A scheme rationalizing the formation of NNN metabolites in the patas monkey is presented in Fig. 6 . The hydroxy acid results from 5Ј-hydroxylation of NNN, as in the rat. It may also be formed by reduction of keto acid. The keto acid most likely is formed by 2Ј-hydroxylation, but it could also be produced from norcotinine (see below). In the patas monkey, 5Ј-hydroxylation of NNN appears to exceed 2Ј-hydroxylation, which is consistent with results obtained in human liver microsomes (Staretz et al., 1997) . Rodent 2Ј-hydroxylation appears to be more extensive than that observed here (Hecht et al., 1981) .
The metabolic conversion of NNN to norcotinine, which may play a central role in NNN metabolism in the patas monkey, is poorly understood. Our earlier studies in rodents suggest that 5Ј-hydroxyNNN and nornicotine are not precursors to norcotinine (McIntee and Hecht, 2000) . Two other potential pathways to norcotinine are shown in Fig. 6 . In one, loss of HNO from NNN would produce isomyosmine, which can be converted to norcotinine by epoxidation followed by spontaneous rearrangement of the epoxide (National Institutes of Health shift). Little is known about the chemical properties of isomyosmine, nor has it been identified as a metabolite in any system to date. Nevertheless, it is possible that this compound could be an intermediate in the formation of both norcotinine and 3Ј-hydroxynorcotinine, as illustrated in Fig. 6 . A second possible intermediate in the formation of both norcotinine and 3Ј-hydroxynorcotinine is ␣-oximinonornicotine (Fig. 6 ). An analogous ␣-oximoamine has been invoked as an intermediate in the formation of metabolites of N-nitrosohexamethyleneimine in the rat (Grandjean, 1976) . ␣-Oximinoamines are known compounds, being produced in the photolysis of nitrosamines (Chow, 1973) , but they have not been isolated as nitrosamine metabolites. Thus, norcotinine and 3Ј-hydroxynorcotinine could both be formed via isomyosmine or ␣-oximinonornicotine.
Further metabolism of norcotinine leads to norcotinine-1-N-oxide, and possibly to 3Ј-hydroxynorcotinine and 3Ј-hydroxynorcotinine-Oglucuronide. Since 3Ј-hydroxycotinine is a major metabolite of cotinine, in humans and rhesus monkeys, it is not unreasonable to propose that 3Ј-hydroxynorcotinine is a metabolite of norcotinine (Dagne and Castagnoli, 1972; Gorrod and Schepers, 1999) . However, we were unable to detect 3Ј-hydroxynorcotinine as a metabolite of norcotinine in vitro with patas monkey liver microsomes (data not shown). Pharmacokinetic considerations also suggest that 3Ј-hydroxynorcotinine is not a metabolite of norcotinine. Moreover, norcotinine is excreted in urine mainly unchanged after administration to rats; the only metabolite detected was the keto acid (Hecht et al., 1981) . Rat liver microsomes convert norcotinine to 4-oxo-4-(3-pyridyl)butyramide and nicotinamide (Eldirdiri et al., 1997) . As mentioned above, 3Ј-hydroxynorcotinine could be produced from isomyosmine or ␣-oximinonornicotine, as well as from norcotinine. The origin of 3Ј-hydroxynorcotinine requires further study.
A major goal of this study was to identify a metabolite that could be used as a biomarker of NNN uptake in humans. Such a metabolite should not be formed from nicotine or other constituents, which are present in tobacco products at levels considerably greater than those of NNN. 3Ј-Hydroxynorcotinine may qualify, but extensive further evaluation, beyond the scope of the present study, would be necessary. 3Ј-Hydroxynorcotinine has not, to our knowledge, been reported as a metabolite of nicotine, nornicotine, cotinine, or norcotinine in any system, and it has not been reported as a constituent of tobacco products. However, we cannot exclude the possibility that it simply has not been found because no standard was available. There are several experiments that should be carried out to further evaluate the potential utility of 3Ј-hydroxynorcotinine as a biomarker of NNN uptake. First, norcotinine and nicotine should be administered to patas monkeys to determine whether 3Ј-hydroxynorcotinine is a urinary metabolite. Second, the urine of nonsmokers who are using nicotine replacement products should be analyzed for 3Ј-hydroxynorcotinine. Third, the urine of smokers should be analyzed for 3Ј-hydroxynorcotinine. If the results of the first two experiments were negative, demonstrating that 3Ј-hydroxynorcotinine is not a metabolite of norcotinine or nicotine, but 3Ј-hydroxynorcotinine were found in appropriate quantities in the urine of smokers, its source likely would be NNN. This possibility could perhaps be further evaluated by analysis of the urine of individuals using low nitrosamine tobacco products.
These proposed experiments are justifiable because previous studies have clearly shown that aspects of the metabolism of the related tobacco-specific nitrosamine NNK are similar in patas monkeys and humans.
In summary, the results of this study demonstrate considerable differences between rodent and patas monkey metabolism of NNN. In particular, norcotinine, 3Ј-hydroxynorcotinine, 3Ј-hydroxynorcotinine-O-glucuronide, and norcotinine-1-N-oxide are all quantitatively significant metabolites of NNN in patas monkey urine whereas the pathways leading to these compounds in rodents are relatively minor or nonexistent.
